Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Lilly to build $3 billion Dutch plant to boost weight-loss pill production
    Finance

    Lilly to build $3 billion Dutch plant to boost weight-loss pill production

    Published by Global Banking & Finance Review®

    Posted on November 3, 2025

    2 min read

    Last updated: January 21, 2026

    Lilly to build $3 billion Dutch plant to boost weight-loss pill production - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:innovationjob creationfinancial managementinvestment

    Quick Summary

    Eli Lilly invests $3B in a Dutch plant to boost weight-loss pill production, creating 500 jobs and expanding its global manufacturing footprint.

    Table of Contents

    • Eli Lilly's Manufacturing Expansion Plans
    • Details of the New Dutch Facility
    • Job Creation and Economic Impact
    • Regulatory Progress for Orforglipron

    Eli Lilly Invests $3 Billion in New Dutch Facility for Weight-Loss Pill

    Eli Lilly's Manufacturing Expansion Plans

    (Reuters) -Eli Lilly said on Monday it plans to build a new $3 billion manufacturing plant in the Netherlands to expand the production capacity for its keenly watched weight-loss pill, orforglipron, and other oral medicines.

    Details of the New Dutch Facility

    The Indianapolis-based drugmaker has shelled out billions of dollars in recent months to boost production of orforglipron, as it proceeds with global regulatory submissions for the pill by the end of the year.

    Job Creation and Economic Impact

    Lilly had said last week orforglipron met most criteria for the U.S. Food and Drug Administration's new national priority voucher, which could shorten drug reviews to one to two months from about 10 to 12 months.

    Regulatory Progress for Orforglipron

    The new European facility would be also used to make oral medicines for diseases related to cardiometabolism, neurology, oncology and immunology, Lilly said.

    The plant, located in Leiden Bio Science Park in Katwijk, Netherlands, will create 500 skilled manufacturing jobs and about 1,500 jobs in construction work, the company said. The construction is expected to start next year.

    The announcement comes days after Lilly announced an over $1.2 billion expansion of its site in Carolina, Puerto Rico, to make orforglipron a part of its previously announced $50 billion U.S. manufacturing push.

    Lilly has said it plans to announce two new U.S. manufacturing sites in the coming months.

    The drugmaker's manufacturing footprint in Europe includes sites in France, Ireland, Italy and Spain.

    (Reporting by Mariam Sunny in Bengaluru; Editing by Sahal Muhammed)

    Key Takeaways

    • •Eli Lilly plans a $3 billion plant in the Netherlands.
    • •The facility will expand production of the weight-loss pill orforglipron.
    • •500 skilled jobs and 1,500 construction jobs will be created.
    • •The plant will also produce medicines for various diseases.
    • •Lilly continues its global manufacturing expansion.

    Frequently Asked Questions about Lilly to build $3 billion Dutch plant to boost weight-loss pill production

    1What is a manufacturing plant?

    A manufacturing plant is a facility where goods are produced using machinery and labor. It is designed for the mass production of products, often involving assembly lines.

    2What is job creation?

    Job creation refers to the process of providing new employment opportunities, often through business expansion, new investments, or economic growth.

    3What is regulatory progress?

    Regulatory progress involves advancements in compliance with laws and regulations that govern industries, ensuring that products meet safety and efficacy standards.

    4What is economic impact?

    Economic impact refers to the effect of an event, policy, or investment on the economy, including job creation, income generation, and overall economic growth.

    More from Finance

    Explore more articles in the Finance category

    Image for French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    Image for Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Image for Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Image for Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Image for Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Image for Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Image for Big Tech's quarter in four charts: AI splurge and cloud growth
    Big Tech's quarter in four charts: AI splurge and cloud growth
    Image for EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    Image for AI trade splinters as investors get more selective
    AI trade splinters as investors get more selective
    Image for EU extends tariff suspension on $109.8 billion of US imports for six months
    EU extends tariff suspension on $109.8 billion of US imports for six months
    Image for Dog food maker Ollie acquired by Spain’s Agrolimen
    Dog food maker Ollie acquired by Spain’s Agrolimen
    Image for Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    View All Finance Posts
    Previous Finance PostLondon stocks dip at start of earnings-heavy, BoE rate verdict week
    Next Finance PostBosch registers furlough measures at Salzgitter site amid chip supply problems